Simple, Easy, Detox.  Body Cleanse Starter Kit

You TubeTwitterFacebook  
Home Ayurvedic Medicine Integrated Medicine Education Contents Articles Links Products Search Feedback Contact Forum Site map
It is currently Mon Apr 23, 2018 11:27 pm

All times are UTC + 7 hours [ DST ]

Post new topic Reply to topic  [ 2 posts ] 
Author Message
PostPosted: Sun May 14, 2006 11:10 am 
Site Admin
User avatar

Joined: Sun May 14, 2006 9:09 am
Posts: 8059
Location: Kuala Lumpur

FDA Removes Panel Member From Drug Review

November 12, 2004; Page A8

A researcher who publicly questioned the safety of Pfizer Inc.'s painkiller Bextra was removed from a Food and Drug Administration advisory panel that will review it and similar products next year.

Curt D. Furberg, a professor at Wake Forest University, Winston-Salem, N.C., said he was informed by the agency that he no longer will participate in the meeting in which the committee will examine the safety of Cox-2 inhibitors, the class of drugs that includes both Bextra and Vioxx, a painkiller that Merck & Co. recently withdrew from the market. Dr. Furberg said he was told by the FDA that his invitation was rescinded because he was quoted in the New York Times as saying Bextra appeared similar to Vioxx and that Pfizer sought to suppress that information.

"They'd said because I had taken a public position, I was disinvited," Dr. Furberg said. He added that he felt he wasn't biased, and he was "trying to be evidence-based" in making findings about Bextra from an analysis of data. "I collected the information to get evidence to contribute to the debate, I drew a conclusion, and I'm off," he said. Dr. Furberg said he still is on the FDA's drug safety and risk management advisory committee, but won't be part of the February Cox-2 meeting.

Sandra Kweder, acting director of the FDA's office of new drugs, said the agency routinely screens advisory committees for possible conflicts, including intellectual as well as financial interests. "If he's already expressed a particular point of view, and especially written a paper on it, it would be difficult to expect him to come to such a meeting and be objective about the subject," she said. Dr. Furberg still could speak before the panel as part of the public-comment period, she said.

The panel is set to review the safety of Bextra and Celebrex, another Pfizer drug, as part of an examination of Cox-2 inhibitors. Vioxx was withdrawn from the market in September by Merck following a clinical trial showing that after 18 months, patients taking it had a higher risk of heart attacks and strokes.

Dr. Furberg was quoted in coverage of an analysis he helped to do that found that patients taking Bextra might be at higher risk for heart attack or stroke.

Pfizer called the findings "unsubstantiated." A Pfizer spokeswoman said the company had nothing to do with Dr. Furberg's departure from the panel. "Pfizer would never intervene in any way with the FDA's regulatory process," she said.

PostPosted: Tue Nov 09, 2010 3:18 pm 
User avatar

Joined: Sun May 14, 2006 11:30 am
Posts: 10319
Location: Kuala Lumpur
Related Topics

• Overdosed America
• Vitamin E Study Misleads Consumers
• Vitamin E May Raise Death Risk
• Alert!! Be Aware of the new FluMist Vaccine !!
• Everyone At Risk From Mad Cow Disease


Global Healing Center® is a leading natural health provider offering natural and organic supplements, cleanses, and a wealth of free natural health articles.

DrEddyClinic Live Blood Microscopy Analysis Dark-field Course

Display posts from previous:  Sort by  
Post new topic Reply to topic  [ 2 posts ] 

All times are UTC + 7 hours [ DST ]

Who is online

Users browsing this forum: No registered users and 2 guests

You cannot post new topics in this forum
You cannot reply to topics in this forum
You cannot edit your posts in this forum
You cannot delete your posts in this forum

Search for:
Jump to:  
Powered by phpBB® Forum Software © phpBB Group